Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacokinetics and ADME Characterization of Intravenous and Oral [14C]-Linerixibat in Healthy Male Volunteers.
Zamek-Gliszczynski MJ, Kenworthy D, Bershas DA, Sanghvi M, Pereira AI, Mudunuru J, Crossman L, Pirhalla JL, Thorpe KM, Dennison JMTJ, McLaughlin MM, Allinder M, Swift B, O'Connor-Semmes RL, Young GC. Zamek-Gliszczynski MJ, et al. Among authors: dennison jmtj. Drug Metab Dispos. 2021 Dec;49(12):1109-1117. doi: 10.1124/dmd.121.000595. Epub 2021 Oct 8. Drug Metab Dispos. 2021. PMID: 34625435 Clinical Trial.
A Novel Inhaled Dry-Powder Formulation of Ribavirin Allows for Efficient Lung Delivery in Healthy Participants and Those with Chronic Obstructive Pulmonary Disease in a Phase 1 Study.
Dumont EF, Oliver AJ, Ioannou C, Billiard J, Dennison J, van den Berg F, Yang S, Chandrasekaran V, Young GC, Lahiry A, Starbuck DC, Harrell AW, Georgiou A, Hopchet N, Gillies A, Baker SJ. Dumont EF, et al. Antimicrob Agents Chemother. 2020 Apr 21;64(5):e02267-19. doi: 10.1128/AAC.02267-19. Print 2020 Apr 21. Antimicrob Agents Chemother. 2020. PMID: 32071044 Free PMC article. Clinical Trial.
Safety, tolerability and pharmacokinetics of emodepside, a potential novel treatment for onchocerciasis (river blindness), in healthy male subjects.
Gillon JY, Dennison J, van den Berg F, Delhomme S, Dequatre Cheeseman K, Peña Rossi C, Strub Wourgaft N, Specht S, Pedrique B, Monnot F, Skrabs S, Rodriguez ML, Stass H. Gillon JY, et al. Br J Clin Pharmacol. 2021 Oct;87(10):3949-3960. doi: 10.1111/bcp.14816. Epub 2021 Mar 31. Br J Clin Pharmacol. 2021. PMID: 33759250 Free PMC article. Clinical Trial.
Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
Pollard AJ, Launay O, Lelievre JD, Lacabaratz C, Grande S, Goldstein N, Robinson C, Gaddah A, Bockstal V, Wiedemann A, Leyssen M, Luhn K, Richert L, Bétard C, Gibani MM, Clutterbuck EA, Snape MD, Levy Y, Douoguih M, Thiebaut R; EBOVAC2 EBL2001 study group. Pollard AJ, et al. Lancet Infect Dis. 2021 Apr;21(4):493-506. doi: 10.1016/S1473-3099(20)30476-X. Epub 2020 Nov 17. Lancet Infect Dis. 2021. PMID: 33217361 Clinical Trial.
Endogenous dopamine release in the human brain as a pharmacodynamic biomarker: evaluation of the new GPR139 agonist TAK-041 with [11C]PHNO PET.
Rabiner EA, Uz T, Mansur A, Brown T, Chen G, Wu J, Atienza J, Schwarz AJ, Yin W, Lewis Y, Searle GE, Dennison JMTJ, Passchier J, Gunn RN, Tauscher J. Rabiner EA, et al. Among authors: dennison jmtj. Neuropsychopharmacology. 2022 Jun;47(7):1405-1412. doi: 10.1038/s41386-021-01204-1. Epub 2021 Oct 21. Neuropsychopharmacology. 2022. PMID: 34675381 Free PMC article.